Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy.

Beard RE, Abate-Daga D, Rosati SF, Zheng Z, Wunderlich JR, Rosenberg SA, Morgan RA.

Clin Cancer Res. 2013 Sep 15;19(18):4941-50. doi: 10.1158/1078-0432.CCR-13-1253. Epub 2013 Sep 10.

2.

PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.

Gezgin G, Luk SJ, Cao J, Dogrusöz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ.

JAMA Ophthalmol. 2017 Jun 1;135(6):541-549. doi: 10.1001/jamaophthalmol.2017.0729.

3.

Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.

Hemminger JA, Toland AE, Scharschmidt TJ, Mayerson JL, Guttridge DC, Iwenofu OH.

Mod Pathol. 2014 Sep;27(9):1238-45. doi: 10.1038/modpathol.2013.244. Epub 2014 Jan 24.

4.

Gene expression profiles of human melanoma cells with different invasive potential reveal TSPAN8 as a novel mediator of invasion.

Berthier-Vergnes O, El Kharbili M, de la Fouchardière A, Pointecouteau T, Verrando P, Wierinckx A, Lachuer J, Le Naour F, Lamartine J.

Br J Cancer. 2011 Jan 4;104(1):155-65. doi: 10.1038/sj.bjc.6605994. Epub 2010 Nov 16.

5.

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.

Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA.

J Natl Cancer Inst. 1996 Jan 17;88(2):100-8.

6.

mRNA expression of tumor-associated antigens in melanoma tissues and cell lines.

Eichmüller S, Usener D, Jochim A, Schadendorf D.

Exp Dermatol. 2002 Aug;11(4):292-301.

PMID:
12190937
7.

Expression profile of genes coding for melanoma differentiation antigens and cancer/testis antigens in metastatic lesions of human cutaneous melanoma.

Zendman AJ, de Wit NJ, van Kraats AA, Weidle UH, Ruiter DJ, van Muijen GN.

Melanoma Res. 2001 Oct;11(5):451-9.

PMID:
11595881
8.

Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy.

Zhang JG, Kruse CA, Driggers L, Hoa N, Wisoff J, Allen JC, Zagzag D, Newcomb EW, Jadus MR.

J Neurooncol. 2008 May;88(1):65-76. doi: 10.1007/s11060-008-9534-4. Epub 2008 Feb 8.

9.

Genomic organization, incidence, and localization of the SPAN-x family of cancer-testis antigens in melanoma tumors and cell lines.

Westbrook VA, Schoppee PD, Diekman AB, Klotz KL, Allietta M, Hogan KT, Slingluff CL, Patterson JW, Frierson HF, Irvin WP Jr, Flickinger CJ, Coppola MA, Herr JC.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):101-12.

10.

MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma.

Gibbs P, Hutchins AM, Dorian KT, Vaughan HA, Davis ID, Silvapulle M, Cebon JS.

Melanoma Res. 2000 Jun;10(3):259-64.

PMID:
10890380
11.

Kinesin family member 20A is a novel melanoma-associated antigen.

Yamashita J, Fukushima S, Jinnin M, Honda N, Makino K, Sakai K, Masuguchi S, Inoue Y, Ihn H.

Acta Derm Venereol. 2012 Nov;92(6):593-7. doi: 10.2340/00015555-1416.

13.

PRAME gene expression in childhood acute lymphoblastic leukemia.

Steinbach D, Viehmann S, Zintl F, Gruhn B.

Cancer Genet Cytogenet. 2002 Oct 1;138(1):89-91.

PMID:
12419593
14.

Development of a Quantitative Real-Time RT-PCR Assay for the Detection of MAGE-A3-Positive Tumors.

Gruselle O, Coche T, Louahed J.

J Mol Diagn. 2015 Jul;17(4):382-91. doi: 10.1016/j.jmoldx.2015.03.008. Epub 2015 May 15.

PMID:
25986000
15.

Expression of BORIS in melanoma: lack of association with MAGE-A1 activation.

Kholmanskikh O, Loriot A, Brasseur F, De Plaen E, De Smet C.

Int J Cancer. 2008 Feb 15;122(4):777-84.

16.

Blood mRNA expression profiling predicts survival in patients treated with tremelimumab.

Saenger Y, Magidson J, Liaw B, de Moll E, Harcharik S, Fu Y, Wassmann K, Fisher D, Kirkwood J, Oh WK, Friedlander P.

Clin Cancer Res. 2014 Jun 15;20(12):3310-8. doi: 10.1158/1078-0432.CCR-13-2906. Epub 2014 Apr 10.

17.

The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis.

Izraely S, Sagi-Assif O, Klein A, Meshel T, Tsarfaty G, Pasmanik-Chor M, Nahmias C, Couraud PO, Ateh E, Bryant JL, Hoon DS, Witz IP.

Int J Cancer. 2012 Sep 1;131(5):1071-82. doi: 10.1002/ijc.27324. Epub 2011 Dec 2.

18.

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, Suciu S, Kruit WH, Eggermont AM, Vansteenkiste J, Brichard VG.

J Clin Oncol. 2013 Jul 1;31(19):2388-95. doi: 10.1200/JCO.2012.44.3762. Epub 2013 May 28.

PMID:
23715562
19.

Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis.

Zou C, Shen J, Tang Q, Yang Z, Yin J, Li Z, Xie X, Huang G, Lev D, Wang J.

Cancer. 2012 Apr 1;118(7):1845-55. doi: 10.1002/cncr.26486. Epub 2011 Aug 26.

20.

Expression of MAGE genes and survival in patients with hepatocellular carcinoma.

Suzuki K, Tsujitani S, Konishi I, Yamaguchi Y, Hirooka Y, Kaibara N.

Int J Oncol. 1999 Dec;15(6):1227-32.

PMID:
10568832

Supplemental Content

Support Center